The company reported strong growth for Kedrab and Cytogam products, with an estimated market share of 40-50%. InnovAte trial enrollment is at 50%, with ongoing discussions with the FDA.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
- SPX
- $5,893.62
- 0.39 %
- $23.00
- DJI
- $43,389.60
- -0.13 %
- -$55.39
- N225
- $38,429.37
- 0.55 %
- $208.52
- FTSE
- $8,109.32
- 0.57 %
- $45.71
- IXIC
- $18,791.81
- 0.6 %
- $111.69